Pipeline

Our pipeline holds proprietary clinical-stage assets and projects in the preclinical and research phases, all aimed at developing and commercializing applications arising from our unique technology platform.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

Pipeline

FluoGuide’s pipeline is under continuous development, yet focused on aggressive brain cancer and lung cancer. However, FluoGuide technology is widely applicable across multiple cancer types.